NetworkNewsBreaks – Achillion (NASDAQ: ACHN) Initiates Patient Dosing in ACH-4471 Phase 2 Study to Treat PNH
Achillion Pharmaceuticals (NASDAQ: ACHN) this morning said it has initiated patient dosing in a phase 2 open-label study of ACH-4471 for patients with paroxysmal nocturnal hemoglobinuria (PNH). ACH-4471 is the company’s first orally-administered, small molecule factor D inhibitor. The study will assess the efficacy, safety, and pharmacokinetics of ACH-4471 in untreated patients with PNH. “We are pleased to have begun this trial in PNH patients to evaluate ACH-4471, the first orally-administered factor D inhibitor to have demonstrated complement alternative pathway (AP) inhibition in humans, which represents a potentially novel and unique mechanistic approach to treating this life-threatening disease,” president and…







